Genentech is pulling Raptiva (efalizumab) from the market due to the risk of an opportunistic brain infection called PML
Genentech is pulling Raptiva (efalizumab) from the market due to the risk of an opportunistic brain infection called PML.
PML (progressive multifocal leukoencephalopathy) is caused by a virus that attacks the brain when the immune system is severely weakened...usually due to AIDS, immunosuppressant therapy, etc.
Several long-term users of Raptiva have developed progressive multifocal leukoencephalopathy...most have died.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote